Invention Grant
- Patent Title: Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
-
Application No.: US15931454Application Date: 2020-05-13
-
Publication No.: US11318113B2Publication Date: 2022-05-03
- Inventor: Philippe Diolez , Dominique Detaille , Frédéric Marin , Olivier Petitjean
- Applicant: OP2 DRUGS , CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE DE BORDEAUX
- Applicant Address: FR Pessac; FR Talence; FR Paris; FR Bordeaux
- Assignee: OP2 DRUGS,CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX,INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE DE BORDEAUX
- Current Assignee: OP2 DRUGS,CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX,INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE DE BORDEAUX
- Current Assignee Address: FR Pessac; FR Talence; FR Paris; FR Bordeaux
- Agency: Nixon & Vanderhye
- Priority: EP15184217 20150908
- Main IPC: A61K31/385
- IPC: A61K31/385 ; A61P9/10 ; A61P3/10 ; A61K31/497
Abstract:
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
Public/Granted literature
- US20200276156A1 COMPOUNDS FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION Public/Granted day:2020-09-03
Information query
